Drew C Deniger

Title: The Innovations of Drew C. Deniger

Introduction

Drew C. Deniger, an accomplished inventor based in Houston, TX, has made significant contributions to the field of immunology. With a focus on advancing cancer treatment, Drew holds two patents that showcase his innovative approaches to T cell receptor (TCR) technologies.

Latest Patents

Drew's latest patents include groundbreaking methods for selectively expanding cells expressing a TCR with a murine constant region. These methods involve modifying human T cells to express a specific TCR that includes a murine constant region. The process enables the selective expansion of T cells that express the TCR over those that do not, which has potential applications in cancer therapy. His second patent focuses on T cell receptors that specifically recognize mutated human p53—an important target in cancer detection and treatment. The patent presents isolated or purified TCRs, additional polypeptides, proteins, and methodologies for detecting and preventing cancer in mammals.

Career Highlights

Drew C. Deniger is associated with the United States of America as represented by the Secretary of the Department of Health and Human Services. His work in this capacity demonstrates a commitment to public health and advancing medical research in the battle against cancer.

Collaborations

In his innovative endeavors, Drew has collaborated with esteemed colleagues such as Steven A. Rosenberg and Anna Pasetto. These collaborations reflect a synergistic approach to research, driving forward the development of effective cancer treatments and enhancing the understanding of T cell receptor biology.

Conclusion

Drew C. Deniger’s innovative contributions to T cell technology and cancer treatment mark him as a significant figure in the field. Through his patents and collaborations, he continues to push the boundaries of medical research, offering hope for improved therapeutic strategies against cancer.